A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs

The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to DMARDs

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: Placebo; Drug: Peficitinib; Biological: Etanercept

Detailed Description

This was a multi-center, randomized, placebo-controlled, double-blind, parallel-group, confirmatory study to evaluate the efficacy and safety of ASP015K alone or in combination with DMARDs in participants with RA who had an inadequate response to DMARDs.

Etanercept was also administered as the reference drug in an open-label manner. The study drug was orally administered once daily (QD) after breakfast for 52 weeks. Etanercept was administered subcutaneously QD for 52 weeks. At Week 12, participants in the placebo group were switched to ASP015K.

The dose of ASP015K to be started at Week 12 for the placebo group was determined randomly at baseline in advance and switched in a blinded manner.

Participants in ASP015K group or placebo groups who had completed the study were eligible for participation in an open-label extension study (015K-CL-RAJ2).

• Study Type: Interventional
• Enrollment (Actual): 509
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Fukuoka, Japan
    • JP00018
  • Fukuoka, Japan
    • JP00020
  • Fukuoka, Japan
    • JP00035
  • Fukuoka, Japan
    • JP00059
  • Fukuoka, Japan
    • JP00067
  • Fukuoka, Japan
    • JP00076
  • Fukuoka, Japan
    • JP00131
  • Fukuoka, Japan
    • JP00164
  • Hiroshima, Japan
    • JP00013
  • Hiroshima, Japan
    • JP00014
  • Hiroshima, Japan
    • JP00016
  • Hiroshima, Japan
    • JP00055
  • Hiroshima, Japan
    • JP00015
  • Kagoshima, Japan
    • JP00074
  • Kagoshima, Japan
    • JP00065
  • Kochi, Japan
    • JP00093
  • Kumamoto, Japan
    • JP00022
  • Kumamoto, Japan
    • JP00046
  • Kyoto, Japan
    • JP00123
  • Kyoto, Japan
    • JP00159
  • Miyagi, Japan
    • JP00023
  • Miyazaki, Japan
    • JP00122
  • Nagano, Japan
    • JP00080
  • Nagasaki, Japan
    • JP00098
  • Nagasaki, Japan
    • JP00112
  • Nagasaki, Japan
    • JP00147
  • Oita, Japan
    • JP00017
  • Okayama, Japan
    • JP00118
  • Osaka, Japan
    • JP00150
  • Osaka, Japan
    • JP00157
  • Shizuoka, Japan
    • JP00089
  • Shizuoka, Japan
    • JP00135
  • Toyama, Japan
    • JP00139
  • Aichi
    • Nagoya, Aichi, Japan
      • JP00037
    • Nagoya, Aichi, Japan
      • JP00109
    • Nagoya, Aichi, Japan
      • JP00130
    • Okazaki, Aichi, Japan
      • JP00066
    • Toyoake, Aichi, Japan
      • JP00140
    • Toyohashi, Aichi, Japan
      • JP00108
    • Toyota, Aichi, Japan
      • JP00156
    • Yatomi, Aichi, Japan
      • JP00068
  • Chiba
    • Kamagaya, Chiba, Japan
      • JP00102
    • Matsudo, Chiba, Japan
      • JP00127
    • Narashino, Chiba, Japan
      • JP00115
    • Yotsukaido, Chiba, Japan
      • JP00138
  • Fukuoka
    • Iizuka, Fukuoka, Japan
      • JP00120
    • Kitakyushu, Fukuoka, Japan
      • JP00040
    • Kitakyushu, Fukuoka, Japan
      • JP00119
    • Kurume, Fukuoka, Japan
      • JP00071
    • Kurume, Fukuoka, Japan
      • JP00106
    • Kurume, Fukuoka, Japan
      • JP00097
  • Gunma
    • Takasaki, Gunma, Japan
      • JP00033
  • Hokkaido
    • Asahikawa, Hokkaido, Japan
      • JP00026
    • Hakodate, Hokkaido, Japan
      • JP00090
    • Kushiro, Hokkaido, Japan
      • JP00125
    • Sapporo, Hokkaido, Japan
      • JP00001
    • Sapporo, Hokkaido, Japan
      • JP00002
    • Sapporo, Hokkaido, Japan
      • JP00003
    • Sapporo, Hokkaido, Japan
      • JP00038
    • Sapporo, Hokkaido, Japan
      • JP00114
    • Sapporo, Hokkaido, Japan
      • JP00031
    • Sapporo, Hokkaido, Japan
      • JP00158
  • Hyogo
    • Akashi, Hyogo, Japan
      • JP00056
    • Himeji, Hyogo, Japan
      • JP00069
    • Kakogawa, Hyogo, Japan
      • JP00113
    • Kato, Hyogo, Japan
      • JP00041
    • Kobe, Hyogo, Japan
      • JP00042
    • Kobe, Hyogo, Japan
      • JP00092
    • Kobe, Hyogo, Japan
      • JP00154
    • Nishinomiya, Hyogo, Japan
      • JP00117
  • Ibaraki
    • Hitachi, Ibaraki, Japan
      • JP00107
    • Koga, Ibaraki, Japan
      • JP00073
    • Mito, Ibaraki, Japan
      • JP00054
  • Iwate
    • Morioka, Iwate, Japan
      • JP00049
  • Kanagawa
    • Isehara, Kanagawa, Japan
      • JP00084
    • Kawasaki, Kanagawa, Japan
      • JP00048
    • Kawasaki, Kanagawa, Japan
      • JP00058
    • Sagamihara, Kanagawa, Japan
      • JP00141
    • Yokohama, Kanagawa, Japan
      • JP00096
    • Yokosuka, Kanagawa, Japan
      • JP00128
  • Kumamoto
    • Tamana, Kumamoto, Japan
      • JP00057
  • Miyagi
    • Sendai, Miyagi, Japan
      • JP00004
    • Sendai, Miyagi, Japan
      • JP00036
    • Sendai, Miyagi, Japan
      • JP00105
    • Sendai, Miyagi, Japan
      • JP00151
    • Sendai, Miyagi, Japan
      • JP00027
  • Miyazaki
    • Hyuga, Miyazaki, Japan
      • JP00050
  • Nagasaki
    • Isehaya, Nagasaki, Japan
      • JP00162
    • Omura, Nagasaki, Japan
      • JP00101
    • Omura, Nagasaki, Japan
      • JP00103
    • Sasebo, Nagasaki, Japan
      • JP00153
  • Nara
    • Kashihara, Nara, Japan
      • JP00094
  • Niigata
    • Nagaoka, Niigata, Japan
      • JP00025
    • Shibata, Niigata, Japan
      • JP00144
  • Oita
    • Beppu, Oita, Japan
      • JP00064
  • Okayama
    • Setouchi, Okayama, Japan
      • JP00051
  • Osaka
    • Hannan, Osaka, Japan
      • JP00011
    • Higashiosaka, Osaka, Japan
      • JP00134
    • Kawachinagano, Osaka, Japan
      • JP00078
    • Sakai, Osaka, Japan
      • JP00137
    • Suita, Osaka, Japan
      • JP00070
    • Suita, Osaka, Japan
      • JP00086
    • Toyonaka, Osaka, Japan
      • JP00061
  • Saga
    • Ureshino, Saga, Japan
      • JP00075
  • Saitama
    • Gyoda, Saitama, Japan
      • JP00126
    • Hiki, Saitama, Japan
      • JP00007
    • Iruma, Saitama, Japan
      • JP00082
    • Kawagoe, Saitama, Japan
      • JP00060
    • Kawagoe, Saitama, Japan
      • JP00161
    • Kawaguchi, Saitama, Japan
      • JP00062
    • Sayama, Saitama, Japan
      • JP00052
    • Tokorozawa, Saitama, Japan
      • JP00008
  • Shizuoka
    • Kakegawa, Shizuoka, Japan
      • JP00133
  • Tochigi
    • Kanuma, Tochigi, Japan
      • JP00077
  • Tokyo
    • Bunkyo, Tokyo, Japan
      • JP00024
    • Bunkyo, Tokyo, Japan
      • JP00149
    • Bunkyo, Tokyo, Japan
      • JP00152
    • Bunkyo, Tokyo, Japan
      • JP00043
    • Chiyoda, Tokyo, Japan
      • JP00099
    • Chiyoda, Tokyo, Japan
      • JP00095
    • Chuo, Tokyo, Japan
      • JP00142
    • Hachioji, Tokyo, Japan
      • JP00063
    • Kiyose, Tokyo, Japan
      • JP00053
    • Meguro, Tokyo, Japan
      • JP00072
    • Meguro, Tokyo, Japan
      • JP00083
    • Ota, Tokyo, Japan
      • JP00148
    • Setagaya, Tokyo, Japan
      • JP00100
    • Shinjuku, Tokyo, Japan
      • JP00032
  • Toyama
    • Takaoka, Toyama, Japan
      • JP00010
  • Wakayama
    • Nishimuro, Wakayama, Japan
      • JP00155
  • Yamaguchi
    • Shimonoseki, Yamaguchi, Japan
      • JP00104
    • Shunan, Yamaguchi, Japan
      • JP00047
• Korea, Republic of
  • Daegu, Korea, Republic of
    • KR00504
  • Daegu, Korea, Republic of
    • KR00510
  • Gwangju, Korea, Republic of
    • KR00505
  • Incheon, Korea, Republic of
    • KR00506
  • Jeonju, Korea, Republic of
    • KR00508
  • Seoul, Korea, Republic of
    • KR00501
  • Seoul, Korea, Republic of
    • KR00502
  • Seoul, Korea, Republic of
    • KR00503
  • Seoul, Korea, Republic of
    • KR00509
  • Seoul, Korea, Republic of
    • KR00511
  • Suwon, Korea, Republic of
    • KR00507
• Taiwan
  • Kaohsiung, Taiwan
    • TW00708
  • Kaohsiung, Taiwan
    • TW00709
  • Taichung, Taiwan
    • TW00704
  • Taichung, Taiwan
    • TW00705
  • Taichung, Taiwan
    • TW00710
  • Tainan, Taiwan
    • TW00712
  • Taipei, Taiwan
    • TW00701
  • Taipei, Taiwan
    • TW00702
  • Taipei, Taiwan
    • TW00711
  • Taoyuan, Taiwan
    • TW00703

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subject has RA diagnosed according to the 1987 American College of Rheumatology (ACR) criteria or the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria

• Subject who did not receive the following drugs, or received the drugs with stable dosage for at least 28 days prior to the baseline (start of treatment) for RA treatment:

  • Non-steroidal anti-inflammatory drugs (NSAIDs; excluding topical formulations), oral morphine or equivalent opioid analgesics (≤ 30 mg/day), acetaminophen, or oral corticosteroids (≤ 10 mg/day in prednisolone equivalent)

• At screening subject has active RA as evidenced by both of the following:

  • ≥ 6 tender/painful joints (using 68-joint assessment)
  • ≥ 6 swollen joints (using 66-joint assessment)
• CRP > 0.50 mg/dL at screening
• Subject meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status in RA Class I, II or, III at screening.
• Inadequate responder to (including subjects who were intolerant of) at least one DMARD administered for at least 90 days prior to screening

Exclusion Criteria:

• Subject has received a biologic DMARD within the specified period
• Subject has received etanercept
• Inadequate responder to at least 3 biologic DMARDs as determined by investigator/sub-investigator
• Subject has received intra-articular, intravenous, intramuscular or endorectal (excluding suppositories for anal diseases) corticosteroid within 28 days prior to baseline
• Subject has participated in any study of ASP015K and has received ASP015K or placebo
• Subject has received other investigational drugs within 90 days or within 5 half-lives, whichever is longer, prior to baseline
• Subject has received plasma exchange therapy within 60 days prior to baseline
• Subject has undergone joint drainage, has received local anesthesia and nerve block, or has received articular cartilage protectant at the assessed joint within 28 days prior to baseline
• Subject has undergone surgery and has residual effects in the assessed joints at the discretion of investigator/sub-investigator, or is scheduled to undergo surgery that may affect the study evaluation of the assessed joints at the discretion of investigator/sub-investigator
• A diagnosis of inflammatory arthritis (psoriatic arthritis, ankylosing spondylitis, SLE, sarcoidosis, etc.) other than RA

• Any of the following laboratory values at screening:

  • Hemoglobin < 9.0 g/dL
  • Absolute neutrophil count < 1000/μL
  • Absolute lymphocyte count < 800/μL
  • Platelet count < 75000/μL
  • ALT ≥ 2 ×ULN
  • AST ≥ 2 × ULN
  • Total bilirubin (TBL) ≥ 1.5 × ULN
  • Estimated GFR ≤ 40 mL/min as measured by the MDRD method
  • β-D-glucan > ULN [in case of Japan: ≥ 11 pg/mL]
  • Positive HBs antigen, HBc antibody, HBs antibody or HBV-DNA quantitation (However, subject with negative HBs antigen and HBV-DNA quantitation, and positive HBc antibody and/or HBs antibody is eligible if HBV-DNA is monitored by HBV-DNA quantitation at every scheduled visit after initiation of study drug or reference drug administration.)
  • Positive HCV antibody
• Subject has a history of or concurrent active tuberculosis (TB)
• Subject has a history of or concurrent interstitial pneumonia and investigator/sub-investigator judges that it is inappropriate for the subject to participate in this study
• Subject has a history of or concurrent malignant tumor (except for successfully treated basal cell carcinoma)
• Subject has received live or live attenuated virus vaccination within 56 days prior to baseline. (Inactivated vaccines including influenza and pneumococcal vaccines are allowed.)
• Subject has a history of or concurrent demyelinating disorders
• Subject has any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, infectious, or autoimmune disease except for RA (excluding Sjogren's syndrome and chronic thyroiditis), or any ongoing illness which would make the subject unsuitable for the study as determined by the investigator/sub-investigator
• Subject has a history of clinically significant allergy. (Clinically significant allergy includes allergies such as systemic urticaria induced by specific antigens and drugs, anaphylaxis, and allergy associated with shock necessitating hospitalized treatment.)
• Subject has concurrent cardiac failure, defined as NYHA classification Class III or higher, or a history of it
• Subject has concurrent prolonged QT syndrome or a history of it. Subject has prolonged QT interval (defined as QTc ≥ 500 msec. Subject has QTc ≥ 500 msec at retest will be excluded) at screening
• Subject has a history of positive HIV infection
• Subject has congenital short QT syndrome or a history of it. Subject has shortened QT interval (defined as QTc < 330 msec. Subject has QTc < 330 msec at retest will be excluded) at screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Participants were assigned to receive placebo to peficitinib once a day until week 12.	Drug: Placebo; oral
Experimental: Peficitinib 100 mg; Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.	Drug: Peficitinib; oral; Other Names: ASP015K
Experimental: Peficitinib 150 mg; Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.	Drug: Peficitinib; oral; Other Names: ASP015K
Active Comparator: Etanercept; Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.	Biological: Etanercept; subcutaneous injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12	The ACR20 response required that all criteria from (1) to (3) below be met.; Tender joint count (TJC) : ≥ 20% reduction compared with baseline.; Swollen joint count (SJC) : ≥ 20% reduction compared with baseline.; ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline (3) ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, Subject's Global Assessment of Arthritis (SGA), Physician's Global Assessment of Arthritis (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), C-Reactive Protein (CRP).	Baseline and Week 12/early termination (ET)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With an ACR20-CRP Response Through Week 52	The ACR20 response required that all criteria from (1) to (3) below be met.; TJC : ≥ 20% reduction compared with baseline.; SJC : ≥ 20% reduction compared with baseline.; ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With an American College of Rheumatology 50% (ACR50)-CRP Response at Week 12	The ACR50 response required that all criteria from (1) to (3) below be met.; TJC : ≥ 50% reduction compared with baseline.; SJC : ≥ 50% reduction compared with baseline.; ≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.	Baseline and Week 12/ET
Percentage of Participants With an ACR50-CRP Response Through Week 52	The ACR50 response required that all criteria from (1) to (3) below be met.; TJC : ≥ 50% reduction compared with baseline.; SJC : ≥ 50% reduction compared with baseline.; ≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With an American College of Rheumatology 70% (ACR70)-CRP Response at Week 12	The ACR70 response required that all criteria from (1) to (3) below be met.; TJC : ≥ 70% reduction compared with baseline.; SJC : ≥ 70% reduction compared with baseline.; ≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.	Baseline and Week 12/ET
Percentage of Participants With an ACR70-CRP Response Through Week 52	The ACR70 response required that all criteria from (1) to (3) below be met.; TJC : ≥ 70% reduction compared with baseline.; SJC : ≥ 70% reduction compared with baseline.; ≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Disease Activity Score (DAS) 28-CRP at Week 12	DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.	Baseline and Week 12/ET
Change From Baseline DAS28-CRP Through Week 52	DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in DAS28-Erythrocyte Sedimentation Rate (ESR) at Week 12	DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.	Baseline and Week 12/ET
Change From Baseline in DAS28-ESR Through Week 52	DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in TJC (68 Joints) at Week 12	The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity. Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).	Baseline and Week 12/ET
Change From Baseline in TJC (68 Joints) Through Week 52	The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity. Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Swollen Joint Count (SJC) (66 Joints) at Week 12	The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity. Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).	Baseline and Week 12/ET
Change From Baseline in SJC (66 Joints) Through Week 52	The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity. Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Achieving DAS28-CRP < 2.6 at Week 12	DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.	Baseline and Week 12/ET
Percentage of Participants Achieving DAS28-CRP < 2.6 Through Week 52	DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Achieving DAS28-ESR < 2.6 at Week 12	DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.	Week 12/ET
Percentage of Participants Achieving DAS28-ESR < 2.6 Through Week 52	DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Achieving DAS28-CRP <= 3.2 at Week 12	DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.	Week 12/ET
Percentage of Participants Achieving DAS28-CRP <= 3.2 Through Week 52	DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Achieving DAS28-ESR <= 3.2 at Week 12	DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.	Week 12/ET
Percentage of Participants Achieving DAS28-ESR <= 3.2 Through Week 52	DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in CRP at Week 12	Higher CRP indicates greater disease activity.	Baseline and Week 12/ET
Change From Baseline in CRP Through Week 52	Higher CRP indicates greater disease activity.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in ESR at Week 12	Higher ESR indicates greater disease activity.	Baseline and Week 12/ET
Change From Baseline in ESR Through Week 52	Higher ESR indicates greater disease activity.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With a European League Against Rheumatism (EULAR) Good Response Using DAS28-CRP at Week 12	Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline > 1.2.	Week 12/ET
Percentage of Participants With a EULAR Good Response Using DAS28-CRP Through Week 52	Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline > 1.2.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP at Week 12	Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline > 0.6, or DAS28 after treatment > 5.1 and improvement from baseline > 1.2.	Week 12/ET
Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP Through Week 52	Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline > 0.6, or DAS28 after treatment > 5.1 and improvement from baseline > 1.2.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With a Good EULAR Response Using DAS28-ESR at Week 12	Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline > 1.2.	Week 12/ET
Percentage of Participants With a Good EULAR Response Using DAS28-ESR Through Week 52	Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline > 1.2.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR at Week 12	Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline > 0.6, or DAS28 after treatment > 5.1 and improvement from baseline > 1.2.	Week 12/ET
Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR Through Week 52	Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline > 0.6, or DAS28 after treatment > 5.1 and improvement from baseline > 1.2.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Achieving ACR / EULAR Remission at Week 12	ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm). Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.	Week 12/ET
Percentage of Participants Achieving ACR / EULAR Remission Through Week 52	ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a VAS of 0 - 100 mm).	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Remission at Week 12	SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3. Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.	Week 12/ET
Percentage of Participants Achieving SDAI Remission Through Week 52	SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in SDAI Score at Week 12	SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description. SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.	Baseline and Week 12/ET
Change From Baseline in SDAI Score Through Week 52	SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description. SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Score <= 2.8 at Week 12	CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description. CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8. Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.	Week 12/ET
Percentage of Participants Achieving CDAI Score <= 2.8 Through Week 52	CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description. CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8.	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in CDAI Score at Week 12	CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description. CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.	Baseline and Week 12/ET
Change From Baseline in CDAI Score Through Week 52	CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description. CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Physician's Global Assessment of Arthritis (PGA) at Week 12	The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.	Baseline and Week 12/ET
Change From Baseline in PGA Through Week 52	The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Subject's SGA at Week 12	The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.	Baseline and Week 12/ET
Change From Baseline in SGA Through Week 52	The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Subject's Assessment of Pain at Week 12	The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.	Baseline and Week 12/ET
Change From Baseline in Subject's Assessment of Pain Through Week 52	The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Number of Participants Who Withdrew Due to Lack of Efficacy	The number of participants who withdrew due to lack of efficacy up to week 12 was calculated.	Up to week 12
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12	The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.	Baseline and Week 12/ET
Change From Baseline in HAQ-DI Through Week 52	The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.	Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Short Form Health Survey - 36 Questions, Version 2 (SF-36v2) Physical Component Summary Score at Week 12	The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.	Baseline and Week 12/ET
Change From Baseline in SF-36v2 Physical Component Summary Score Through Week 52	The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.	Baseline and Week 4, 8, 12, 28, and 52
Change From Baseline in SF-36v2 Mental Component Summary Score at Week 12	The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.	Baseline and Week 12/ET
Change From Baseline in SF-36v2 Mental Component Summary Score Through Week 52	The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.	Baseline and Week 4, 8, 12, 28, and 52
Change From Baseline in SF-36v2 Role/Social Component Summary Score at Week 12	The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.	Baseline and Week 12/ET
Change From Baseline in SF-36v2 Role/Social Component Summary Score Through Week 52	The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.	Baseline and Week 4, 8, 12, 28, and 52
Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Percent Work Time Missed at Week 12	WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).	Baseline and Week 12/ET
Change From Baseline in WPAI Percent Work Time Missed Through Week 52	WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).	Baseline and Week 4, 8, 12, 28, and 52
Change From Baseline in WPAI Percent Impairment While Working at Week 12	WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.	Baseline and Week 12/ET
Change From Baseline in WPAI Percent Impairment While Working Through Week 52	WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.	Baseline and Week 4, 8, 12, 28, and 52
Change From Baseline in Percent Overall Work Impairment at Week 12	WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].	Baseline and Week 12/ET
Change From Baseline in WPAI Percent Overall Work Impairment Through Week 52	WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].	Baseline and Week 4, 8, 12, 28, and 52
Change From Baseline in WPAI Percent Activity Impairment at Week 12	WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.	Baseline and Week 12/ET
Change From Baseline in WPAI Percent Activity Impairment Through Week 52	WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.	Baseline and Week 4, 8, 12, 28, and 52
Number of Participants With Adverse Events During the First 12 Weeks	Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.	Week 0 to Week 12
Number of Participants With Adverse Events From Week 12	Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.	Week 12 to week 52, plus 28 days after the week 52 visit for participants who did not enroll in the extension study

Collaborators and Investigators

• Sponsor: Astellas Pharma Inc
• Investigators: Study Director: Medical Director, Astellas Pharma Inc

Publications and helpful links

General Publications

• Toyoshima J, Shibata M, Kaibara A, Kaneko Y, Izutsu H, Nishimura T. Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2021 Apr;87(4):2014-2022. doi: 10.1111/bcp.14605. Epub 2020 Dec 1.
• Tanaka Y, Takeuchi T, Izutsu H, Kaneko Y, Kato D, Fukuda M, Rokuda M, Schultz NM. Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. Arthritis Res Ther. 2021 Aug 24;23(1):221. doi: 10.1186/s13075-021-02590-z.
• Toyoshima J, Kaibara A, Shibata M, Kaneko Y, Izutsu H, Nishimura T. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis. Pharmacol Res Perspect. 2021 May;9(3):e00744. doi: 10.1002/prp2.744.
• Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, Chen YH, Wei JC, Lee SH, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Akazawa R, Shiomi T, Yamada E. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019 Oct;78(10):1320-1332. doi: 10.1136/annrheumdis-2019-215163. Epub 2019 Jul 26.

Helpful Links

• Link to results on Astellas Clinical Study Results website

Study record dates

Study Major Dates

• Study Start (Actual): August 8, 2014
• Primary Completion (Actual): January 23, 2017
• Study Completion (Actual): November 22, 2017

Study Registration Dates

• First Submitted: December 2, 2014
• First Submitted That Met QC Criteria: December 2, 2014
• First Posted (Estimated): December 4, 2014

Study Record Updates

• Last Update Posted (Actual): October 28, 2024
• Last Update Submitted That Met QC Criteria: October 17, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: Rheumatoid Arthritis; ASP015K
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Joint Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Arthritis; Arthritis, Rheumatoid; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Peripheral Nervous System Agents; Gastrointestinal Agents; Enzyme Inhibitors; Antirheumatic Agents; Sensory System Agents; Analgesics, Non-Narcotic; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Etanercept; Peficitinib
• Other Study ID Numbers: 015K-CL-RAJ3

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
• IPD Sharing Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
• IPD Sharing Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes